BioSpace News Archive

OptiNose, Inc. announced that the company has granted a non-qualified stock option award to purchase 100,000 shares of its common stock to a new employee as an inducement material for accepting employment with OptiNose.

SQI Diagnostics Inc. announced that the Company’s board of directors has received a notice of intention to enforce security issued by its senior secured creditor, Pivot Financial I Limited Partnership, under Section 244 of the Bankruptcy and Insolvency Act.

Navidea Biopharmaceuticals, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series K Preferred Stock, par value $0.001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on June 27, 2023.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), announced today that it has entered into a restructuring agreement (“Amending Agreement”) with K2 HealthVentures (“K2HV”) to satisfy and discharge MTEM’s outstanding secured debt obligations and terminate all other obligations under the existing debt financing facility between Molecular Templates and K2HV.

Coeptis Therapeutics Holdings, Inc. announced the closing of an underwritten offering for gross proceeds of approximately $3.5 million to a single healthcare focused investor prior to deducting underwriting discounts and commissions and offering expenses.

Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced financial results for the first quarter of 2023, including growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate).

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (“Prometheus”) (NASDAQ: RXDX) acquisition.

Stoke Therapeutics, Inc. announced that, effective on June 15, 2023, the company granted stock options to purchase an aggregate of 26,900 shares of common stock to 2 new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635.

Biophytis SA announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Annual General Meeting.

vTv Therapeutics Inc. announced that Cantex Pharmaceuticals, Inc. recently obtained an exclusive worldwide license from Georgetown University for intellectual property related to the potential use of azeliragon to treat, prevent or alleviate cancer treatment-related cognitive decline.